Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy by Estelle Tran Van Hoi, Saskia J. Santegoets, Simon P. Mooijaart, Diana Van Heemst, Asli Özkan, Elizabeth M. E. Verdegaal, Marije Slingerland, Ellen Kapiteijn, Sjoerd H. van der Burg, Johanneke E. A. Portielje, Marij J. P. Welters, Nienke A. de Glas

Get full text

Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refrac... by Gerrit-Jan Liefers, Sjoerd H van der Burg, Monique K van der Kooij, Marten Visser, Linda de Bruin, Ellen Kapiteijn, Els M E Verdegaal, Caroline E van der Minne, Pauline M Meij, Inge C F M Roozen, Mare A Jonker, Shelley van den Bosch, Frank M Speetjens

Get full text

Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma by Diane van der Woude, Theo Rispens, Catharina M Korse, Sjoerd H van der Burg, Ellen Kapiteijn, John B A G Haanen, Winan J van Houdt, Els M E Verdegaal, Marij J P Welters, Jessica S W Borgers, Tineke J van Wesemael, Johannes V van Thienen, Kyra A Gelderman, Dirk J A R Moes

Get full text